Alpha Tau announces acceptance into FDA’s TPLC TAP Pilot

Alpha Tau (DRTS) Medical announced that it has been accepted into the prestigious Total Product Life Cycle, TPLC, Advisory Program, TAP, Pilot of the U.S. Food and Drug Administration, FDA, to accelerate market access to the Alpha DaRT for patients with recurrent glioblastoma multiforme, GBM. This acceptance follows the Company’s previous receipt of Breakthrough Device Designation from the FDA for this indication, one of two such designations received for the Alpha DaRT, and a pre-requisite for application to the TAP program.